Docoh
Loading...

NVAX Novavax

Novavax, Inc. is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

Company profile

Ticker
NVAX
Exchange
Website
CEO
Stanley Erck
Employees
Incorporated
Location
Fiscal year end
SEC CIK
IRS number
222816046

NVAX stock data

(
)

Calendar

10 May 21
1 Aug 21
31 Dec 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Novavax earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 2.03B 2.03B 2.03B 2.03B 2.03B 2.03B
Cash burn (monthly) (positive/no burn) (positive/no burn) 69.54M 50.2M (positive/no burn) (positive/no burn)
Cash used (since last report) n/a n/a 282.91M 204.24M n/a n/a
Cash remaining n/a n/a 1.75B 1.82B n/a n/a
Runway (months of cash) n/a n/a 25.1 36.3 n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
26 Jul 21 Herrmann John A III Common Stock Sell Dispose S No Yes 204.5671 68 13.91K 706
26 Jul 21 Herrmann John A III Common Stock Sell Dispose S No Yes 203.4545 58 11.8K 774
26 Jul 21 Herrmann John A III Common Stock Sell Dispose S No Yes 202.5764 129 26.13K 832
26 Jul 21 Herrmann John A III Common Stock Sell Dispose S No Yes 201.5614 209 42.13K 961
26 Jul 21 Herrmann John A III Common Stock Sell Dispose S No Yes 200.4742 256 51.32K 1,170
26 Jul 21 Herrmann John A III Common Stock Sell Dispose S No Yes 199.466 224 44.68K 1,426
26 Jul 21 Herrmann John A III Common Stock Sell Dispose S No Yes 198.2032 317 62.83K 1,650
26 Jul 21 Herrmann John A III Common Stock Sell Dispose S No Yes 197.4697 485 95.77K 1,967
26 Jul 21 Herrmann John A III Common Stock Sell Dispose S No Yes 196.1202 313 61.39K 2,452
26 Jul 21 Herrmann John A III Common Stock Sell Dispose S No Yes 195.2891 263 51.36K 2,765

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

56.7% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 383 347 +10.4%
Opened positions 100 98 +2.0%
Closed positions 64 53 +20.8%
Increased positions 98 114 -14.0%
Reduced positions 135 83 +62.7%
13F shares
Current Prev Q Change
Total value 7.6B 4.7B +61.6%
Total shares 41.99M 38.88M +8.0%
Total puts 3.55M 4.89M -27.3%
Total calls 4.2M 3.35M +25.3%
Total put/call ratio 0.8 1.5 -42.0%
Largest owners
Shares Value Change
Vanguard 5.89M $1.07B +5.3%
BLK Blackrock 5.47M $992.32M +6.8%
FMR 4.79M $868.64M +173.7%
Ra Capital Management 3M $544.31M -20.8%
STT State Street 1.44M $261.44M -16.5%
Wellington Management 1.42M $258.08M +289.2%
BEN Franklin Resources 1.31M $236.68M +2.1%
Geode Capital Management 1.11M $200.89M +15.6%
TROW T. Rowe Price 822.77K $149.18M +137.8%
NTRS Northern Trust 800.46K $145.13M -14.9%
Largest transactions
Shares Bought/sold Change
FMR 4.79M +3.04M +173.7%
Wellington Management 1.42M +1.06M +289.2%
Perceptive Advisors 0 -1.04M EXIT
Ra Capital Management 3M -786.48K -20.8%
Susquehanna International 495.61K -744.34K -60.0%
Renaissance Technologies 672.68K +672.68K NEW
Capital World Investors 617.83K -567.91K -47.9%
Norges Bank 0 -558.69K EXIT
Carmignac Gestion 529.17K +529.17K NEW
TROW T. Rowe Price 822.77K +476.75K +137.8%

Financial report summary

?
Risks
  • We are a biotechnology company and face significant risk in developing, manufacturing and commercializing our products.
  • Because we depend on third-parties to conduct some of our laboratory testing and clinical trials, and a significant amount of our vaccine manufacturing and distribution, we may encounter delays in or lose some control over our efforts to develop and supply products.
Management Discussion
  • Revenue for the three months ended March 31, 2021 was $447.2 million as compared to $3.4 million for the same period in 2020, an increase of $443.9 million. Revenue for the three months ended March 31, 2021 was primarily comprised of revenue for services performed under the OWS Agreement and the CEPI Funding Agreement. Revenue for the three months ended March 31, 2020 was primarily comprised of revenue for services performed under the CEPI Funding Agreement, BMGF Grant Agreement and revenue from Novavax AB. The significant increase in revenue was due to increased development activities relating to NVX-CoV2373 under the OWS Agreement and the CEPI Funding Agreement.
  • We expect revenue in 2021 to significantly increase as compared with 2020 due to our NVX-CoV2373 program, which we anticipate will continue to be funded by OWS and CEPI and/or other revenue sources. Further, we anticipate bringing our NVXCoV2373 vaccine candidate to market following global regulatory approvals which, if achieved, should significantly increase revenue. In anticipation, we have entered into various advance purchase agreements as well as multiple supply and license agreements with strategic partners to supply NVX-CoV2373 in their specified territories under which we are entitled to receive royalty revenue from the sale of NVX-CoV2373 by such partners. 
  • In the three months ended March 31, 2021, our research and development activities were primarily focused on the development of NVX-CoV2373 and included direct external research and development expenses related to NVX-CoV2373 of $538.1 million, primarily comprised of costs related to the following:
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: add, addressing, adolescent, African, allegedly, American, analytical, APA, APC, Asian, attended, back, Barnard, baseline, begun, boost, boosted, booster, boosting, breach, Burkina, Canadian, cardiovascular, Castle, catchment, CDMO, Centre, Chancery, characterization, CMC, CMO, complaint, composed, constituting, consulting, Council, Court, COVID, CRO, crossover, Delaware, demographic, description, disgorgement, durability, duty, East, en, endemic, enrichment, ensure, entry, escape, EUA, examination, examine, exhibit, exhibited, expansion, experienced, explore, exploring, Faso, fiduciary, forefront, foregoing, formally, formulated, Fourteen, frequency, fueled, fulfil, Golubinski, ground, GSK, hand, harmonized, headcount, Healthcare, HollisterStier, hypertension, IgG, Immunisation, IND, injection, internationally, inventory, Jenner, jointly, Jubilant, Kenya, Korean, la, Lancet, Latin, listing, lymph, Majesty, Mali, mechanism, Medsafe, Memorandum, memory, MHLW, MHRA, microgram, middle, Minister, mix, Montreal, MOU, Nanoro, Native, nominal, notably, obesity, online, open, optimistic, optimize, Oxford, parallel, pending, pipeline, plaintiff, PMDA, possessed, potent, predetermined, presence, prohibited, purport, purpose, quantity, Queen, randomly, raw, ready, reassuring, Recherche, regiment, rescinding, revoked, round, royalty, Sant, SAR, seronegative, seropositive, shortage, Spokane, stockholder, subset, summarized, Switzerland, Tanzania, TGA, thirty, tiered, today, unamortized, unbilled, Understanding, undisclosed, unique, unjust, unsatisfied, upfront, validation, variant, viability, Washington, waste, withholding, Zealand
Removed: academic, acceptable, acceptance, accessibility, accessible, account, accrued, adequately, adjustment, adjuvanted, adversely, affordable, Aid, allocating, allocation, aluminum, anniversary, assigning, asthma, awarded, biological, biopharmaceutical, BLA, blocked, bring, burden, calculate, calculated, Catalent, certainty, charge, China, choice, chronic, closed, collectively, combat, commercialized, competitive, competitor, conditional, confidence, congestive, contemplated, continuity, convenient, core, CoV, create, curtailed, customer, cybersecurity, decade, declared, decreased, deduction, deemed, degree, delayed, derived, developed, difficult, diminished, diminishing, disaster, disclosed, disrupted, disruption, distancing, dosing, dramatic, Ebola, EBOV, economic, eliminating, emerged, enacted, enactment, enhanced, escrow, essentially, establish, exacerbation, execute, expensive, experience, extensive, extreme, failed, failure, family, fatal, fewer, flu, forecast, fringe, GACA, genetic, geographic, GlaxoSmithKline, glycoprotein, governmental, GP, grow, healthy, heart, heavily, home, hospital, identify, immunosenescence, impairment, imposed, impossible, inadequate, inception, incidence, independently, indirect, indirectly, industry, Inovio, insect, institution, invest, investor, Johnson, July, Larger, licensing, longer, lot, LRTI, manner, marketing, Maryland, maternal, measurement, meet, minimum, Moderna, mortality, natural, necessitate, negatively, obstructive, occur, offering, outbreak, overhead, Paragon, paused, people, perform, personnel, Pfizer, phosphate, political, power, predicted, pregnant, preliminary, Prepare, prioritization, produced, professional, prolongation, prospectively, prove, proven, pulmonary, pursue, pursuing, quality, quantitative, rapid, reaching, record, recruitment, reduced, reducing, regulated, reimbursed, relief, remotely, requirement, resulted, ResVax, ResVaxTM, safer, Sanofi, satisfy, School, season, sequence, side, social, spread, step, substantial, subtracting, successful, successfully, surface, target, terrorism, test, threat, timely, tract, travel, treated, trimester, twelve, type, uncertain, uncertainty, Union, unpredictable, utilized, viral, volatile, vulnerable, waiting, war, water, weather, women